Literature DB >> 3871341

Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin.

P Casellas, X Canat, A A Fauser, O Gros, G Laurent, P Poncelet, F K Jansen.   

Abstract

In view of bone marrow purging before autologous transplantation in T cell malignancies, an anti-human T cell immunotoxin (IT) has been prepared by coupling ricin A-chain to the monoclonal antibody T101 that binds the T1 differentiation antigen expressed by T lymphocytes as well as by T cell-derived hematologic malignancies. Using a sensitive and reliable clonogenic assay, optimal conditions were defined for the elimination of clonogenic human T leukemic cells among bone marrow cells. Maximal cytoreduction was obtained with IT at a dose of 2 micrograms/mL in the presence of 10 mmol/L NH4Cl. This treatment led to the reduction of more than six orders of magnitude of T101-positive clonogenic leukemic cells, with no harm to T101-negative cells. Moreover, we observed no toxicity of IT to human hematopoietic stem cells (CFU-GEMMT) derived from bone marrow of healthy volunteers. Thus, pretreatment of bone marrow samples with IT plus NH4Cl offers a safe, simple, reliable, and highly efficient means to eliminate undesirable leukemic T cells from the graft.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871341

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.

Authors:  M Chiron; J P Jaffrezou; P Carayon; C Bordier; F Roubinet; C Xavier; M Brandely; G Laurent
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 2.  Drug-targeting by monoclonal antibodies.

Authors:  M J Embleton
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

Review 3.  Immunotoxins: the role of the toxin.

Authors:  Antonella Antignani; David Fitzgerald
Journal:  Toxins (Basel)       Date:  2013-08-21       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.